← Back to Clinical Trials
Recruiting NCT06744764

NCT06744764 Pulsed Electromagnetic Fields in Preventing Physical Deconditioning in Patients Undergoing Prolonged Hospitalization

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06744764
Status Recruiting
Phase
Sponsor National University Hospital, Singapore
Condition Haematological Cancer
Study Type INTERVENTIONAL
Enrollment 76 participants
Start Date 2023-04-17
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
PEMF (1mT)PEMF (0mT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 76 participants in total. It began in 2023-04-17 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to examine if pulsed electromagnetic fields (PEMF) can prevent or decrease physical deconditioning associated with prolonged hospitalisation and immobility of haematology patients. The main question\[s\] it aims to answer \[is/are\]: * Does haematology patients undergoing prolonged hospitalisation have no or decreased physical deconditioning when exposed to PEMF? * What are the changes in muscle secretome at baseline and after exposure to PEMF? Researchers will compare haematology patients who receive PEMF against patients who did not receive the treatment to see if there is a change in physical deconditioning. Healthy volunteers will also be recruited and randomized to either exposure to PEMF or no exposure. Haematology patients will * Have their blood taken at baseline, 4 weeks from baseline and 8 weeks from baseline. * Undergo SPPB test at baseline, 4 weeks and 8 weeks from baseline, and the test comprises of the time up and go test, 4 minute walk test and sit to stand test. * Either expose to PEMF twice per week for 4 consecutive weeks or no exposure. Healthy volunteers will * Have their blood taken at baseline, 4 weeks from baseline and 8 weeks from baseline. * Either expose to PEMF twice per week for 4 consecutive weeks or no exposure.

Eligibility Criteria

Inclusion Criteria: * Haematology patients who are undergoing induction chemotherapy for acute leukemia * Haematology patients who are undergoing haematopoietic stem cell transplant * Have ECOG 0-24. Able to walk at baseline to participate in short physical battery test. * For healthy volunteers, subjects have to be healthy without any major disease states, not on any drugs or requiring long term medical attention. Exclusion Criteria: * Patients who do not agree to sign the consent form. * Pregnant women will be excluded from the study for healthy volunteers

Contact & Investigator

Central Contact

Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath,

✉ melissa_ooi@nuhs.edu.sg

📞 6772 2526

Frequently Asked Questions

Who can join the NCT06744764 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 99 Years, studying Haematological Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06744764 currently recruiting?

Yes, NCT06744764 is actively recruiting participants. Contact the research team at melissa_ooi@nuhs.edu.sg for enrollment information.

Where is the NCT06744764 trial being conducted?

This trial is being conducted at Kent Ridge, Singapore, Kent Ridge, Singapore.

Who is sponsoring the NCT06744764 clinical trial?

NCT06744764 is sponsored by National University Hospital, Singapore. The trial plans to enroll 76 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology